Article

Men with cT3 PCa may benefit from surgery

San Antonio--Urologists who might have bypassed the option of surgery to send patients with clinical T3 (cT3) disease directly to a radiation oncologist might want to rethink the way they refer patients, according to a new study.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Kevin T. McVary, MD, FACS, answers a question during a Zoom video interview
Expert discusses setting realistic expectations for Rezum for BPH
1 expert is featured in this series.
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Nicolette G. Payne, MD, answers a question during a Zoom video interview
Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists
Andrea Pezzella, MD, URPS, FACOG, answers a question during a Zoom video interview
Sacral neuromodulation device empowers patients with greater UUI control
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Study: Women with SCI are more likely to use indwelling catheters
Discover the Art and Science Behind Nerve Sparing Prostate Surgery
Discover the Art and Science Behind Nerve Sparing Prostate Surgery
Ziho Lee, MD, previews 2025 Northwestern GU robotic reconstruction course
Ziho Lee, MD, previews 2025 Northwestern GU robotic reconstruction course
Related Content
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: © Dr_Microbe - stock.adobe.com
July 21st 2025

Darolutamide plus ADT approved in EU for mHSPC

Hannah Clarke
This approval enables the use of darolutamide plus ADT with or without chemotherapy.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
Experts urge FDA to remove black box warning on low-dose vaginal estrogen
July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke
In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
Urology in focus: Key moments from 2025
July 18th 2025

Urology in focus: Key moments from 2025

Hannah Clarke
Take a look back through some of the top stories from the first half of the year.
3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
July 18th 2025

Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT

Hannah Clarke
The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.
© 2025 MJH Life Sciences

All rights reserved.